基于糖蛋白E的带状疱疹疫苗研究进展
Research progress in herpes zoster vaccine based on glycoprotein E
杨梦瑶 1裴银辉 2段招军3
作者信息
- 1. 华北理工大学基础医学院河北省慢性疾病基础医学重点实验室,唐山 063000;中国疾病预防控制中心病毒病预防控制所传染病溯源预警与智能决策全国重点实验室 国家卫生健康委医学病毒和病毒病重点实验室 北京 102206
- 2. 华北理工大学基础医学院河北省慢性疾病基础医学重点实验室,唐山 063000
- 3. 中国疾病预防控制中心病毒病预防控制所传染病溯源预警与智能决策全国重点实验室 国家卫生健康委医学病毒和病毒病重点实验室 北京 102206
- 折叠
摘要
水痘-带状疱疹病毒首次感染引发水痘痊愈后,会潜伏于人体的脊神经节等部位.随着年龄的增长及机体免疫力的下降,病毒会重新激活引起嗜神经性的带状成簇水泡皮损,累及腰胸部皮肤,称为带状疱疹.目前,临床上并无特效药能够及时有效地预防和控制水痘带状疱疹病毒的感染和复发.鉴于水痘-带状疱疹病毒糖蛋白E(gE)独特的免疫原优势,已成为国内外开发带状疱疹疫苗的重要靶抗原.本文综述了目前全球基于gE的新型带状疱疹疫苗研究进展,期望对我国新一代带状疱疹疫苗的研发提供借鉴和参考.
Abstract
After the first infection with varicella-zoster virus causes chickenpox and recovers,it will lurk in the spinal ganglia and other parts of the body.As people age and immunity declines,the virus reactivates and causes neurotropic bands of blisters that mainly affect the skin of the waist and chest,known as herpes zoster.At present,there is no specific drug that can prevent and control the infection and recurrence of varicella-zoster virus infection.In view of the unique immunogenic advantages of varicella-zoster virus glycoprotein E(gE),it has become an important target antigen for the development of herpes zoster vaccine at home and abroad.This article reviews the current research progress of new gE-based herpes zoster vaccine in the world,hoping to provide reference for the research and development of a new generation of herpes zoster vaccine in China.
关键词
水痘-带状疱疹病毒/带状疱疹疫苗/gE蛋白Key words
Varicella-zoster virus/Herpes zoster vaccine/Glycoprotein E引用本文复制引用
出版年
2024
NETL
NSTL
万方数据